Abstract: Objective To compare the clinical anti-tumor effect of cytokine-induced killer cells(CIK) derived from patients with malignancies or healthy doners. Methods Peripheral blood mononuclear cells(PBMC) of patients(n=12) or healthy doners(n=12) were cultured in presence of IFN-γ, CD3 Ab, IL-1 and IL-2. The proliferation was counted by Trypan blue test, the in vitro anti-tumor cytotoxicity was analysed by CCK-8 assay, the phenotypes were analyzed by flow cytometry, the duration of healthy CIK was determined by PCR, the clinical effects were compared finally. Results Compared with autologous CIK, healthy CIK showed higher proliferative ability and enhanced in vitro anti-tumor cytotoxicity(P<0.05), and led to an efficient recovery of immunologic function of recipients. 5～8w after infusion, healthy CIK could also be detected in recipients’ peripheral blood. More importantly, healthy CIK showed equivalent therapeutic effect and minimal adverse reactions. Conclusion Application of healthy CIK cells in treatment of malignancies is efficient and feasible, which would gain a better clinic application prospect.

Key words: cytokine-induced killer cells, malignancy, T lymphocyte subset